Patrick G. Enright - 25 Sep 2024 Form 4 Insider Report for BioAge Labs, Inc. (BIOA)

Reporting relationship: Director
Issuer ticker: BIOA
Reported as of: 25 Sep 2024
Net transaction value: +$7,200,000
SEC form: 4
Accepted by SEC: 27 Sep 2024, 16:26:41 UTC
Prior SEC filing: 16 Sep 2024
Next SEC filing: 16 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Dov A. Goldstein as attorney-in-fact

Key filing fact

Patrick G. Enright filed Form 4 for BioAge Labs, Inc. (BIOA) on 27 Sep 2024.

Key facts

This page summarizes Patrick G. Enright's Form 4 filing for BioAge Labs, Inc. (BIOA).
4 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 27 Sep 2024, 16:26.

Change

Previous filing in this sequence was filed on 16 Sep 2024.
Current net transaction value: +$7,200,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BIOA transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +1,310,589
Change %
Price
Shares after: 1,310,589
Date: 27 Sep 2024
Ownership: Longitude Venture Partners IV, L.P.
Footnotes: F1, F2

BIOA transaction

Common Stock

Purchase

Transaction value: $7,200,000
Shares: +400,000
Change %: +31%
Price: $18.00
Shares after: 1,710,589
Date: 27 Sep 2024
Ownership: Longitude Venture Partners IV, L.P.
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BIOA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +15,000
Change %
Price: $0.000000
Shares after: 15,000
Date: 25 Sep 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $18.00
Footnotes: F3

BIOA transaction Derivative

Series D Preferred Stock

Conversion of derivative security

Transaction value
Shares: -5,848,637
Change %: -100%
Price
Shares after: 0
Date: 27 Sep 2024
Ownership: Longitude Venture Partners IV, L.P.
Underlying class: Common Stock
Underlying amount: 1,310,589
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614. The securities have no expiration date.

Footnote F2

These shares are directly held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to exercise voting and investment discretion with respect to securities held by LVP IV. The reporting person and Ms. Juliet Tammenoms Bakker serve as the managing members of LCP IV and may be deemed to share voting and investment discretion with respect to securities held directly by LVP IV. Each of LCP IV, Mr. Enright, and Ms. Tammenoms Bakker disclaims beneficial ownership of such securities and this report shall not be deemed an admission that any of them is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose, except to the extent of their respective pecuniary interests therein.

Footnote F3

The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date.